Condition: Metastatic Renal Cell Carcinoma · Clear-cell Metastatic Renal Cell Carcinoma · Neuroendocrine Tumors · Sponsor: Fox Chase Cancer Center
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
This description comes directly from the study's public registry record.
Ryan Romasko · 888-369-2427 · ryan.romasko@fccc.edu
Always discuss trial participation with your own doctor first.
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05263050